Who is sponsoring NCT05488769?

NCT05488769 is sponsored by Thomas Nagy.

What drugs are being tested in NCT05488769?

Interventions in NCT05488769: Clareon Vivity extended depth of focus (EDOF) intraocular lens.

Is NCT05488769 still recruiting?

NCT05488769 is currently terminated. Last updated 19 January 2023.

Last reviewed 2023-01-19 · How we verify

NCT05488769

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Visual Outcomes and Patient Satisfaction After Bilateral Implantation of Non-diffractive EDOF IOL Made of a New Hydrophobic Acrylic Material

Terminated Last updated 19 January 2023

What this trial tests

trial testing Clareon Vivity extended depth of focus (EDOF) intraocular lens in Cataract in 6 participants. Terminated before completion.

Timeline

25 August 2022

Primary endpoint
29 November 2022

29 November 2022

Quick facts

Lead sponsor	Thomas Nagy
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	6
Start date	25 August 2022
Primary completion	29 November 2022
Estimated completion	29 November 2022
Sites	1 location across Canada

Drugs / interventions tested

Clareon Vivity extended depth of focus (EDOF) intraocular lens

Conditions studied

Cataract — all drugs for Cataract →

Sponsor

Thomas Nagy

Who can join

Eligibility, any sex, with Cataract. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective is to measure the range of vision and patient reported visual disturbances after bilateral implantation for this unique non-diffractive extended depth of focus (EDOF) intraocular lens (IOL) made from the Clareon material.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cataract

Currently open trials in the same condition.

NCT07301385 — Evaluation of Head-Mounted Spatial Computing and Three-Dimensional (3D) Visualization in Ocular Microsurgery: A Safety a · NA · recruiting
NCT07462000 — Aqueous Humor and Ocular Tissue Analysis in Glaucoma and Cataract · NA · recruiting
NCT06891092 — Vivinex Impress XY1-EM vs RayOne EMV · NA · recruiting
NCT07218796 — Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compar · Phase 3 · recruiting
NCT07218783 — Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compar · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05488769 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Thomas Nagy
Last refreshed: 19 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05488769.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing